Activated lymphocyte from umbilical cord blood, preparations containing it as main content and method therefor

A technology for lymphocytes and umbilical cord blood is applied in the fields of activated lymphocytes derived from umbilical cord blood, preparations containing the lymphocytes as main components, and preparation of the preparations and complete sets of equipment, and can solve the problems of unfavorable absorption of inoculated cells, etc., To achieve the effect of eliminating viral infections, eliminating the possibility of viral infections and recurrence of tumors

Inactive Publication Date: 2002-08-14
HUMANTEC
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, umbilical cord blood vaccination may lead to tumor recurrence at a higher frequenc...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0021] A method for preparing cord blood-derived activated lymphocytes and a pharmaceutical preparation containing activated lymphocytes as a main component according to the present invention will be described in detail herein below. [Cord Blood Collection]

[0022] The cord blood-derived activated lymphocytes of the present invention can be obtained by activating and proliferating cord blood collected from the umbilical cord. It is advisable to draw cord blood from the blood vessels of the umbilical cord. Additionally, heparin or citric acid may be added to the collected cord blood to prevent the collected cord blood from clotting. A portion of cord blood held for transplantation in a cord blood bank may be used. The activated lymphocytes derived from umbilical cord blood according to the present invention can be prepared from 0.001 ml to 100 ml of umbilical cord blood. [Activated Lymphocytes from Cord Blood]

[0023] Proliferation of activated lymphocytes derived from um...

experiment Embodiment approach 11

[0049] It is advisable to administer the preparation according to the invention to the patient by injection or intravenous infusion. It is more preferable to use an injection or an intravenous drip containing physiological saline to which the aforementioned cells are added so that the concentration of human serum albumin is 0.01% to 5%. Administration of the formulations according to the invention may suitably be carried out by intravenous drip or injection into veins, arteries or locally. Although the amount of the preparation to be administered depends on the administration method or site, it is advisable to administer 1 to 500 ml of the preparation. It is more preferable to use a desired amount of a preparation containing the aforementioned specified amount of cells. The frequency of administration of the formulations of the invention to patients is recommended to be from once a day to once a month, with the formulations being administered at least once. [Experimental emb...

experiment Embodiment approach 2

[0066] Likewise, CD45RA antibody (imported and sold by Nippon Becton Dickinson Company, Ltd., product No. 347723) and CD45RO antibody (imported and sold by Nippon Becton Dickinson Company, Ltd., product No. positive analysis for 347967). The analysis results showed that the ratios of CD45RA and CD45RO were 7% and 73%, respectively. Because activated lymphocytes derived from cord blood were actually positive for CD45RO, they were considered to achieve superior antitumor effects and protection against infection. [Experimental embodiment 2] Culture of umbilical cord blood mononuclear cells

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Activated lymphocytes derived from cord blood are excellently effective for preventing and treating various types of tumors and various types of infection. With interleukin 2 and/or anti-CD3 antibody, the lymphocytes derived from the cord blood is prepared by segregating lymphocytes from the cord blood and proliferating the segregated lymphocytes directly in vitro or segregating monocytes from cord blood and proliferating the monocytes in vitro. Also, the cord blood-derived activated lymphocytes can be effectively used for preventing recurrence of the diseases and promoting the take of stem cells or other organs.

Description

technical field [0001] The present invention relates to activated lymphocytes derived from umbilical cord blood, pharmaceutical preparations containing the aforementioned lymphocytes as main components, and methods and kits for preparing the aforementioned preparations, which are used for treating various tumors and infectious diseases and preventing these diseases Occurrence and recurrence, as well as to accelerate the absorption of stem cells in various organs, etc. Background technique [0002] Recently, intense interest has been shown in lymphocytes that make the immune system resistant to biological defenses. In particular, T-lymphocytes are one of the important cells with effective cellular immunity, and are classified into the following groups according to the reactivity of monoclonal antibodies. For example, T-lymphocytes reactive to anti-CD3 antibody (CD is an abbreviation for Cluster of differentiation) are CD3 positive cells. Much research has...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/17A61K35/26A61K35/44A61K35/51A61K38/00A61P31/00A61P31/04A61P31/12A61P35/00A61P37/00A61P37/02C12N5/07C12N5/0783C12N5/0789C12R1/91
CPCC12N2501/515C12N5/0636C12N2501/23A61K2039/5158A61P31/00A61P31/04A61P31/12A61P35/00A61P37/00A61P37/02
Inventor 关根晖彬伊藤仁也清水则夫马场宪三山口智宏黑岩保幸
Owner HUMANTEC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap